Healthcare acquired infection devices, pharmaceuticals, and environmental products

  • 498 views
Uploaded on

This report is a valuable tool for anyone assessing the healthcare-acquired infection market and attempting to devise a strategy to successfully compete in this market. It provides background on the …

This report is a valuable tool for anyone assessing the healthcare-acquired infection market and attempting to devise a strategy to successfully compete in this market. It provides background on the structure of the HAI market and the chief challenges and opportunities it faces. It offers the information needed to understand the current market and to address the emerging one.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
498
On Slideshare
0
From Embeds
0
Number of Embeds
1

Actions

Shares
Downloads
6
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Healthcare-Acquired Infection: Devices, Pharmaceuticals, and EnvironmentalProductsPublished:September 2011No.of Pages:224Price:US $ 4850Report Summary* The global market for healthcare-acquired infection (HAI) treatments were$16 billion in year 2010. This market is estimated to be around $19 billion inthe year 2011 and is forecasted to cross $30 billion by 2016 at a CAGR of9.5% for five year period.* Markets for infection control devices and products were $8.3 billion in theyear 2010 and are expected to reach $10.3 billion by 2011. This market isforecasted to cross $18.3 billion by 2016 at a CAGR of 12%.* The market for pharmaceutical treatments is expected to be around $4.5billion. This market is expected to increase at a 5.8% compound annualgrowth rate (CAGR) to reach $6 billion by 2016.INTRODUCTIONREASONS FOR DOING THE STUDYThe objective of this study is to provide an in-depth analysis and forecast ofthe selected areas of the global healthcare-acquired infection market. HAI issometimes used to mean hospital-acquired infections, but for purposes ofthis report, HAI includes hospitals, nursing homes, outpatient surgerycenters, and dialysis centers. Another term for healthcare-acquiredinfections is nosocomial infections.The focus of this report is on devices, pharmaceuticals, and therapiescurrently used or under development for treatment of viral, bacterial, orfungal infections.The global market for HAI products is estimated at between $10 billion and$15 billion in 2010, depending on the products included in the study, withhigh single-digit growth through 2016. Although the U.S. holds between45% and 50% of the market, the fastest-growing regions for HAI treatmentsare the Asia-Pacific, which includes China, and Brazil.
  • 2. STUDY GOALS AND OBJECTIVESHealthcare-acquired infections are viral, bacterial, or fungal infections thatpatients acquire after they are admitted to a healthcare facility. Patients canacquire these infections from routine care; surgery; or as a complicationfrom the use of medical devices such as ventilators, catheters, andintravenous lines.The Centers for Disease Control (CDC) estimates that 2 million HAIs occurannually in the U.S. This leads to 100,000 deaths and costs an additional$36 billion to $45 billion in direct medical costs annually.The report Healthcare-Acquired Infection: Devices, Pharmaceuticals, andEnvironmental Products is designed to investigate the global HAI market bytreatment area and by treatment type, with supporting tables and figures toillustrate projected growth. The report will include the U.S., Europe, Japan,and other countries such as China.This report offers forecasts of the markets for devices, pharmaceuticals, andtherapies by treatment segment and treatment type from 2011 through2016, including supporting analyses for projections.This report is a valuable tool for anyone assessing the healthcare-acquiredinfection market and attempting to devise a strategy to successfully competein this market. It provides background on the structure of the HAI marketand the chief challenges and opportunities it faces. It offers the informationneeded to understand the current market and to address the emerging one.This is an invaluable tool for business planners; acquisition specialists;licensing strategists; product managers; market research analysts; investingconsultants; and others interested in the HAI market, its products, itsparticipants, and its future.Browse All Pharmaceuticals Market Research ReportsMETHODOLOGIES AND INFORMATION SOURCESInformation for this report was obtained from various primary and secondaryresearch sources, including industry analysts, annual reports, Securities andExchange Commission (SEC) reports, the World Health Organization (WHO),the National Institutes of Health (NIH), American Hospital Association (AHA),Infectious Disease Society of America (IDSA), American Society of Heating,Refrigerating and Air Conditioning Engineers (ASHRAE), National Institute of
  • 3. Allergy and Infectious Diseases (NIAID), the National Hospital DischargeSurvey (NHDS), government agencies outside the U.S, and journal articles.Secondary sources include literature searches, product literature, and pressreleases.When precise information was unavailable, a consensus is made usingreasonable assumptions and estimates based on historical data.Table Of ContentsCHAPTER ONE: INTRODUCTIONREASONS FOR DOING THE STUDYSTUDY GOALS AND OBJECTIVESMETHODOLOGIES AND INFORMATION SOURCESANALYST CREDENTIALSRELATED BCC REPORTSBCC ONLINE SERVICESDISCLAIMERCHAPTER TWO: SUMMARYSUMMARY TABLE GLOBAL MARKET FOR HAI TREATMENTS, THROUGH 2016($ MILLIONS)SUMMARY FIGURE GLOBAL MARKET FOR HAI TREATMENTS BYGEOGRAPHICAL AREA, 2010 AND 2016 (%)CHAPTER THREE: OVERVIEWTABLE 1 GLOBAL PREVALENCE OF HEALTHCARE-ACQUIRED INFECTIONS(PER 100 PATIENTS)IMPORTANCE OF HAND WASHINGMOST COMMON HEALTHCARE-ASSOCIATED INFECTIONSTABLE 2 CAUSES AND TYPES OF HEALTHCARE-ACQUIRED INFECTIONSGRAM-POSITIVE BACTERIAS. AUREUSTransmission RoutesMRSARate of InfectionTransmission RoutesTYPES OF PNEUMONIAPseudomonas AeruginosaHospital-Acquired PneumoniaKlebsiella PneumoniaCLOSTRIDIUM DIFFICILEMYCOBACTERIUM TUBERCULOSIS
  • 4. Scope of InfectionE. COLIUTI Treatment OptionsGASTROENTERITIS-CAUSING BACTERIATreatment OptionsVANCOMYCIN-RESISTANT ENTEROCOCCITypes of VRELEGIONELLA BACTERIATreatment OptionsGRAM-NEGATIVE BACTERIAPSEUDOMONAS AERUGINOSAACINETOBACTER BAUMANNIISTENOTROPHOMONAS MALTOPHILIAVIRAL INFECTIONSVIRAL INFECTION RESEARCHHEPATITIS B AND CScope of InfectionTreatmentHIVTreatmentNOROVIRUSINFLUENZA VIRUSInfluenzavirus A, B, CTransmissionSymptomsTreatmentRESPIRATORY SYNCYTIAL VIRUSTreatmentFUNGAL INFECTIONSASPERGILLUS INFECTIONSTreatmentYEAST INFECTIONSCandida InfectionsPREVENTING HAIDETERMINING THE MODE OF TRANSMISSIONCDC RECOMMENDATIONS FOR PREVENTIONTABLE 3 CDC MEASURES FOR PREVENTION OF HEALTHCAREACQUIREDINFECTIONS, 2007ROLES OF HEALTHCARE INSTITUTIONS AND INFECTION CONTROLINDIVIDUALSTABLE 4 SELECTED RESPONSIBILITIES OF INFECTION CONTROL TEAMMEMBERSCOMPONENTS OF A HAI SURVEILLANCE SYSTEM
  • 5. TABLE 5 MAIN STEPS AND COMPONENTS IN DEVELOPING AN EFFECTIVEINFECTION-CONTROL SURVEILLANCE SYSTEMSUITABLE SURVEYS IN DEVELOPING COUNTRIESHEALTHCARE INFECTION POINTS OF GENERATIONHOSPITALSSURGICAL PROCEDURESAMBULATORY SURGERY CENTERS IN THE U.S.Number of Procedures in ASCsInfection Control in ASCsDIALYSIS CENTERSU.S. Dialysis CentersTransmission of VREHepatitis Transmission in U.S. Dialysis CentersHepatitis Transmission in Dialysis Centers Outside the U.S.ASSISTED LIVING AND LONG-TERM CARE FACILITIESTREATMENTSPROACTIVE MEASURESEnvironmental ControlsDevice DesignREACTIVE MEASURESCHANGES IN THE INDUSTRYTABLE 6 SELECTED MERGERS AND/OR ACQUISITIONS, 2005-2011 ($MILLIONS)CHAPTER FOUR: GLOBAL HEALTHCARE-ACQUIRED INFECTIONMARKETU.S. MARKETU.S. HEALTHCARE SPENDINGSCOPE OF HEALTHCARE-ACQUIRED INFECTIONS IN U.S.Ventilator-Associated PneumoniaRATE OF INFECTIONIntensive Care UnitsSurgical Site InfectionsFungal InfectionsCOSTSU.S. PREVENTION ACTION PLANTABLE 7 HHS ACTION PLAN FOR HAI PREVENTION (% REDUCTION)EUROPEAN MARKETSCOPEHELICSRATE OF INFECTION AND COSTSJAPANESE MARKETSCOPE
  • 6. RATE OF INFECTIONCHINESE MARKETSCOPERATE OF INFECTIONREST OF THE WORLD MARKETSCOPERATE OF INFECTIONOPPORTUNITIES AND CHALLENGES FOR HAI INDUSTRYMEDICAL DEVICE OPPORTUNITIES AND CHALLENGESChallengesENVIRONMENTAL AND STRUCTURAL OPPORTUNITIES AND CHALLENGESChallengesNEW TREATMENTSPHARMACEUTICAL MARKET OPPORTUNITIES AND CHALLENGESTABLE 8 SELECTED HAI-RELATED PHARMACEUTICAL PATENT EXPIRATIONS,2005-2020Pipeline LimitationsGlobal RecessionRegulatory RestrictionsGeneric CompetitionIMPACT OF DEMOGRAPHIC CHANGESDEMOGRAPHIC CHANGES IN THE U.S.DEMOGRAPHIC CHANGES OUTSIDE THE U.S.CHAPTER FIVE: HAI PHARMACEUTICAL MARKETGLOBAL MARKETSROLE OF EMERGING NATIONSPHARMACEUTICALS USED FOR HEALTHCARE-ACQUIRED INFECTIONSTABLE 9 GLOBAL MARKET FOR HAI PHARMACEUTICALS BY TYPE, THROUGH2016 ($ MILLIONS)GLOBAL GROWTH RATES FOR PHARMACEUTICALSTABLE 10 ESTIMATED GROWTH OF PHARMACEUTICAL HEALTHCARESPENDING BY REGION, THROUGH 2016 (%)VIRAL HAI PHARMACEUTICALSTABLE 11 SELECTED VIRAL HAI PHARMACEUTICALS BY NAME, INDICATION,AND MANUFACTURER, 2010FIGURE 1 ESTIMATED GLOBAL MARKET SHARE FOR PRESCRIPTIONPHARMACEUTICALS TO TREAT VIRAL HAI BY COMPANY, 2010 (%)FIGURE 2 GLOBAL MARKET FOR VIRAL BY DISEASE TYPE(%)VIRAL PHARMACEUTICAL MARKET BY CONDITIONTABLE 12 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT VIRAL HAIBY CONDITION, THROUGH 2016 ($ MILLIONS)BACTERIAL HAI PHARMACEUTICALS
  • 7. TABLE 13 SELECTED BACTERIAL HAI PHARMACEUTICALS BY NAME,INDICATION, AND MANUFACTURER, 2010DRUG CLASSESAminoglycosidesB-Lactam AntibioticsCephalosporinsGlycopeptidesLincosamidesLipopeptidesCarbapenemsPenicillinsPolypeptidesMacrolidesQuinolonesTetracyclinesTuberculosisSulfonamidesOther FormulationsFIGURE 3 GLOBAL MARKET SHARE FOR PRESCRIPTION PHARMACEUTICALSTO TREAT BACTERIAL HAI BY COMPANY, 2010 (%)TABLE 14 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT BACTERIALHAI, THROUGH 2016 ($ MILLIONS)TABLE 15 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT BACTERIALHAI BY CONDITION, THROUGH 2016 ($ MILLIONS)FUNGAL HAI PHARMACEUTICALSTABLE 16 SELECT LISTING OF PHARMACEUTICALS TO TREAT FUNGALINFECTIONS BY NAME, TYPE, AND MANUFACTURER, 2010TABLE 17 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT FUNGAL HAI,THROUGH 2016 ($ MILLIONS)FIGURE 4 MARKET FOR PHARMACEUTICALS TO TREAT FUNGAL HAI BYCOMPANY, 2010 (%)GLOBAL OPPORTUNITIESCHAPTER SIX: HAI ENVIRONMENTAL TREATMENT MARKETGLOBAL HAI ENVIRONMENTAL TREATMENT MARKETTABLE 18 GLOBAL MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TOMINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2016 ($MILLIONS)PLANNING FOR CONSTRUCTION OR RENOVATION: U.S.Plans Involving Infection ControlAIR TREATMENTROOM FILTRATION SYSTEMSROOM PRESSURIZATION
  • 8. HYDROGEN PEROXIDE VAPORDedicated Airborne Isolation RoomsWATER TREATMENTDESIGN OF SINKS AND OTHER WATER FACILITIESCLEANING PHYSICAL SURFACESDISINFECTIONAdvantages and Disadvantages of DisinfectantsTABLE 19 ADVANTAGES AND DISADVANTAGES OF COMMONLY USEDDISINFECTANTSPHENOLICSOXIDIZING AGENTSHALOGENSALDEHYDESQUATERNARY AMINESALCOHOLSTABLE 20 GLOBAL MARKET FOR DISINFECTANT PRODUCTS DESIGNED TOMINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2016 ($MILLIONS)FIGURE 5 GLOBAL MARKET FOR DISINFECTANT PRODUCTS BY TYPE, 2010(%)PATIENT SKIN PREPARATION DISINFECTANTSIODINEPOVIDONE-IODINE SOLUTIONSCHLORHEXIDINE GLUCONATETABLE 21 GLOBAL MARKET FOR PATIENT PREPARATION DISINFECTANTS,THROUGH 2016 ($ MILLIONS)STERILIZATION SYSTEMS FOR INFECTION CONTROLTABLE 22 GLOBAL MARKET FOR STERILIZATION DESIGNED TO MINIMIZEHEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2016 ($ MILLIONS)CHEMICAL STERILIZATIONETO SterilizationMajor Players in Chemical SterilizationOTHER CHEMICAL STERILIZATIONPeracetic AcidHydrogen PeroxideChlorine DioxideOzoneSTEAM STERILIZATIONTABLE 23 SELECTED PLASTIC MATERIALS THAT RESPOND WELL TO STEAMSTERILIZATIONAutoclavingMajor Players in Heat Sterilization
  • 9. CHAPTER SEVEN: HAI MEDICAL DEVICES: CATHETERS, PATIENTVENTILATION SYSTEMS, AND IN-LINE STERILIZATION FILTERSSELECTED GLOBAL MEDICAL HAI DEVICE MARKETTABLE 24 GLOBAL MARKET FOR MEDICAL DEVICES THAT MINIMIZEHEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2016 ($ MILLIONS)CATHETERSUSE OF COATINGSCATHETER COATINGSTABLE 25 SELECTED CATHETER PRODUCTS WITH ANTIBIOTIC PROPERTIESSilver CoatingSURFACE-MODIFIED CATHETERTABLE 26 GLOBAL MARKET FOR CATHETERS WITH ANTIMICROBIALPROPERTIES, THROUGH 2016 ($ MILLIONS)FIGURE 6 HAI CATHETER MARKET SHARES BY URINARY, CVC, PICC, ANDOTHER SEGMENTS, 2011 AND 2016 (%)URINARY TRACT CATHETERSCENTRAL VENOUS CATHETERSDialysis CathetersCatheter-Related Bloodstream InfectionsTABLE 27 POTENTIAL SOURCES OF CRBSIPERIPHERALLY INSERTED CENTRAL VENOUS CATHETERSMARKET OPPORTUNITIES FOR CATHETER MANUFACTURERSCATHETER GROWTH IN REGIONAL MARKETSTABLE 28 GLOBAL HAI CATHETER MARKET BY REGION, THROUGH 2016 ($MILLIONS)FIGURE 7 GLOBAL HAI CATHETER MARKET BY REGION, 2011 AND 2016 (%)PATIENT VENTILATION DEVICESTABLE 29 GLOBAL MARKET FOR PATIENT VENTILATION PRODUCTS,THROUGH 2016 ($ MILLIONS)TYPES OF VENTILATION DEVICESNon-Invasive VentilatorsTABLE 30 GLOBAL MARKET FOR NON-INVASIVE VENTILATIONS SYSTEMSFOR USE WITH PATIENTS WHO HAVE HAIS, THROUGH 2016 ($ MILLIONS)ENDOTRACHEAL TUBES AND VENTILATION SYSTEMSCoated Endotracheal TubesTapered Endotracheal TubesTABLE 31 GLOBAL MARKET FOR COATED ENDOTRACHEAL TUBES DESIGNEDTO MINIMIZE VAP, THROUGH 2016 ($ MILLIONS)IN-LINE STERILE IV FILTRATIONTABLE 32 GLOBAL STERILE IV FILTER MARKET, THROUGH 2016 ($MILLIONS)
  • 10. CHAPTER EIGHT: REGULATIONS AND PATENTSU.S. INFECTION CONTROL PROGRAMSINFECTION CONTROL MEASURES AND PROTOCOLSU.S. REGULATIONSHOSPITAL INFECTIONS DISCLOSURE ACTCURRENT AND PENDING REQUIREMENTSAffordable Care Act and Implications for the Pharmaceutical IndustryBiosimilarsCMS Reimbursement for HAIsEUROPEAN REGULATIONSIMPLICATIONS FOR PHARMACEUTICAL MANUFACTURERSJAPANESE REGULATIONSCHINESE REGULATIONSPATENTSPATENTS BY MANUFACTURERTABLE 33 PATENTS BY MANUFACTURER, 2005-2011PATENTS BY DATE OF ISSUETABLE 34 PHARMACEUTICAL PATENTS BY DATE OF ISSUE, 2005-2011PATENTS BY MANUFACTURERTABLE 35 PATENTS BY MANUFACTURERPATENTS FOR DELIVERY OF PHARMACEUTICALSTABLE 36 PATENT BY INDICATION: PHARMACEUTICAL DELIVERY, 2005-2011BACTERIAL PHARMACEUTICAL PATENTSTABLE 37 PATENTS BY INDICATION: BACTERIAL PHARMACEUTICAL, 2005-2011FUNGAL PHARMACEUTICAL PATENTSTABLE 38 PATENT BY INDICATION: FUNGAL PHARMACEUTICAL, 2010VIRAL PHARMACEUTICAL PATENTSTABLE 39 PATENTS BY INDICATION: VIRAL PHARMACEUTICAL, 2005-2011ENVIRONMENTAL CONTROLSTABLE 40 PATENT BY INDICATION: AIR FILTRATION, 2005-2011TABLE 41 PATENTS BY INDICATION: WATER TREATMENT, 2005-2011PATENTS FOR SURFACE DISINFECTANTSTABLE 42 PATENTS BY INDICATION: DISINFECTANT SURFACES, 2005-2011TABLE 43 PATENT BY INDICATION: SOLID WASTE TREATMENT, 2005-2011PATENTS FOR DIAGNOSTIC PROCESSESTABLE 44 PATENTS BY INDICATION: DIAGNOSTIC, 2006-2011MEDICAL DEVICESTABLE 45 PATENTS BY INDICATION: CATHETER, 2008-2011TABLE 46 PATENTS BY INDICATION: ANTIMICROBIAL COATINGS, 2005-2011
  • 11. CHAPTER NINE: CURRENT RESEARCH AND EMERGING THERAPIESEMERGING RESEARCHRAPID TESTINGANTISEPTIC WASHESPHARMACEUTICALSMERCKBoceprivirVERTEXTeleprivirTIBOTECCEREXACeftarolineNXL104BASILEA PHARMACEUTICALSCeftobiproleDelafloxacinJOHNSON & JOHNSONDoribaxCUBIST PHARMACEUTICALSCSA-201CXA183,315TOYAMA CHEMICALT-705T-3912T-2307GLAXOSMITHKLINEOPTIMER PHARMACEUTICALSFidaxomicinAURICXBPH-652PFIZERTHE MEDICINES COMPANYOritavancinSTERILIZATION AND DISINFECTIONSHARKLET TECHNOLOGIESHEALTHCARE FACILITY DESIGNMEDICAL DEVICE DESIGNONDINE BIOMEDICALCERAGENIX PHARMACEUTICALS, INC.RENAL SEPSIS MICROFILTERCHAPTER TEN: COMPANY PROFILES
  • 12. PHARMACEUTICALSABBOTT LABORATORIESBusiness OverviewFinancialsProductsASTELLAS PHARMA, INC.Business OverviewFinancial InformationProductsASTRA TECHASTRAZENECA, PLCBusiness OverviewFinancialsProductsBACTIGUARD, ABBusiness OverviewFinancialsProductsBASILEA PHARMACEUTICA, LTD.Business OverviewFinancialsProductsBAYER, AG (MILES-BAYER)Business OverviewFinancialsProductsBOEHRINGER INGELHEIM, GMBHBusiness OverviewFinancialsProductsBRISTOL-MYERS SQUIBBBusiness OverviewFinancialsProductsCEREXA, INC. (FOREST LABORATORIES)Business OverviewFinancialsProductsCUBIST PHARMACEUTICALSBusiness OverviewFinancialsProductsELAN CORPORATION
  • 13. Business OverviewFinancialsProductsFOREST LABORATORIESBusiness OverviewFinancialsProductsELI LILLY AND COMPANYBusiness OverviewFinancialsProductsGILEAD SCIENCESBusiness OverviewFinancialsProductsGLAXOSMITHKLINEBusiness OverviewFinancialsProductsJOHNSON & JOHNSONBusiness OverviewFinancial InformationProductsMEDIMMUNE PHARMACEUTICALSBusiness OverviewFinancialsProductsMERCKBusiness OverviewFinancialsProductsNABI BIOPHARMACEUTICALSBusiness OverviewFinancialsProductsPFIZERBusiness OverviewFinancialsProductsROCHE PHARMACEUTICALSBusiness OverviewFinancialsProducts
  • 14. SANOFI AVENTISBusiness OverviewFinancialsProductsSCHERING-PLOUGHTHE MEDICINES COMPANYBusiness OverviewFinancialsProductsTHERAVANCEBusiness OverviewFinancialsProductsTOYAMA CHEMICAL CO, LTD.Business OverviewFinancialsProductsVERTEX PHARMACEUTICALS, INC.Business OverviewFinancialsProductsVIROPHARMA, INC.Business OverviewFinancialsProductsENVIRONMENTAL PRODUCTS3M HEALTHCARE, MEDICAL DIVISIONBusiness OverviewFinancialsProductsADVANCED STERILIZATION PRODUCTSBusiness OverviewFinancialsProductsANDERSEN PRODUCTS, INC.Business OverviewFinancialsProductsBAXTER INTERNATIONALBusiness OverviewFinancialsProductsDIVERSEY, INC
  • 15. Business OverviewFinancialsProductsECOLABBusiness OverviewFinancialsProductsGETINGE USA, INC.Business OverviewFinancialsProductsPRIMUS STERILIZER CO., INC.Business OverviewFinancialsProductsRUHOF CORP.Business OverviewFinancialsProductsSTERIGENICSBusiness OverviewFinancialsProductsSTERIS CORP.Business OverviewFinancialsProductsTUTTANAUER USA CO., LTD.Business OverviewFinancialsProductsULTRAVIOLET DEVICES, INC.Business OverviewFinancialsProductsXENEX HEALTHCARE SERVICESBusiness OverviewFinancialsProductsINFECTION CONTROL DEVICESB. BRAUN MELSUNGEN, AGBusiness OverviewFinancials
  • 16. ProductsBECTON DICKINSONBusiness OverviewFinancialsProductsBIOMÉRIEUX, INC.Business OverviewFinancialsProductsCANTEL MEDICAL CORP.Business OverviewFinancialsProductsCAREFUSION CORP.Business OverviewFinancialsProductsCEPHEIDBusiness OverviewFinancialsProductsCLOROX CO.Business OverviewFinancialsProductsCOLOPLAST GROUPBusiness OverviewFinancialsProductsCONVATECBusiness OverviewFinancialProductsCOOK MEDICALBusiness OverviewFinancialsProductsCOVIDIEN, PLCBusiness OverviewFinancialsProductsCR BARDBusiness Overview
  • 17. FinancialsProductsDRAGER MEDICAL, LTD., U.K.Business OverviewFinancialsProductsHOLLISTER, INC.Business OverviewFinancialsProductsKIMBERLY-CLARK HEALTHCAREBusiness OverviewFinancialsProductsODINE BIOMEDICAL, INC.Business OverviewFinancialsProductsTELEFLEX MEDICALBusiness OverviewFinancialsProductsWELCH ALLYN, INC.Business OverviewFinancialsProductsAbout Us:ReportsnReports is an online library of over 100,000+ market researchreports and in-depth market research studies & analysis of over 5000 micromarkets. We provide 24/7 online and offline support to our customers. Getin touch with us for your needs of market research reports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page:http://www.facebook.com/pages/ReportsnReports/191441427571689
  • 18. Contact:Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comVisit our Market Research Blog